1. Home
  2. CCEL vs ATNM Comparison

CCEL vs ATNM Comparison

Compare CCEL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.65

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.00

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
ATNM
Founded
1989
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
31.7M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
CCEL
ATNM
Price
$3.65
$1.00
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
9.5K
120.9K
Earning Date
04-14-2026
05-06-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
14.17
EPS
0.01
N/A
Revenue
$25,384,279.00
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$353.90
N/A
Revenue Growth
9.76
11.11
52 Week Low
$2.72
$0.94
52 Week High
$5.43
$1.89

Technical Indicators

Market Signals
Indicator
CCEL
ATNM
Relative Strength Index (RSI) 50.57 40.81
Support Level $3.08 N/A
Resistance Level $3.92 $1.27
Average True Range (ATR) 0.33 0.05
MACD -0.00 0.00
Stochastic Oscillator 55.57 13.54

Price Performance

Historical Comparison
CCEL
ATNM

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: